Dr. Michael Jensen is the Founder and Chief Scientific Officer of BrainChild Bio, a clinical-stage biotech company pioneering CAR T-cell therapies to treat tumors in the central nervous system, with a primary focus on children with deadly brain cancers.

A physician-scientist and graduate of the University of Pennsylvania School of Medicine, Dr. Jensen spent 13 years at Seattle Children's Therapeutics as its founding Chief Therapeutics Officer, leading R&D and conducting four landmark CAR T-cell clinical trials in nearly 100 pediatric patients.

Dr. Jensen is an internationally recognized leader in CAR T-cell immunotherapy with over 200 patents in cell and gene therapy, more than 130 peer-reviewed articles, and 30 years of experience translating cutting-edge science into clinical therapies for children with cancer.

He co-founded Juno Therapeutics, which was acquired by Celgene and led to the commercialization of Breyanzi, a now-approved CAR T-cell therapy for lymphoma, and also co-founded Umoja Biopharma, where he serves on the Scientific Advisory Board.

BrainChild Bio closed a $116 million Series A in September 2026, earned FDA Breakthrough Therapy Designation for its lead therapy BCB-276, and initiated a pivotal Phase 2 trial for DIPG, one of the most devastating and incurable pediatric brain cancers.